Characterization of the effect of the GLUT-1 inhibitor BAY-876 on T cells and macrophages.

[1]  Xiaoxi Wang,et al.  Identification of a novel GLUT1 inhibitor with in vitro and in vivo anti-tumor activity. , 2022, International journal of biological macromolecules.

[2]  F. Schumacher,et al.  The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming. , 2022, Cell metabolism.

[3]  Jan Dudek,et al.  Pharmacological Inhibition of GLUT1 As a New Immunotherapeutic Approach After Myocardial Infarction. , 2021, Biochemical pharmacology.

[4]  F. Martel,et al.  The in vitro effect of the diabetes-associated markers insulin, leptin and oxidative stress on cellular characteristics promoting breast cancer progression is GLUT1-dependent. , 2021, European journal of pharmacology.

[5]  Kellen L. Olszewski,et al.  Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer , 2020, Nature Cell Biology.

[6]  D. Mann,et al.  Reappraising the role of inflammation in heart failure , 2020, Nature Reviews Cardiology.

[7]  B. Haibe-Kains,et al.  GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer , 2019, Nature Communications.

[8]  R. Diaz,et al.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.

[9]  Shu-Wha Lin,et al.  The Combination of MK-2206 and WZB117 Exerts a Synergistic Cytotoxic Effect Against Breast Cancer Cells , 2019, Front. Pharmacol..

[10]  H. Saya,et al.  Glucose transporter 1‐mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[11]  F. Setién,et al.  Epigenetic loss of the endoplasmic reticulum-associated degradation inhibitor SVIP induces cancer cell metabolic reprogramming. , 2019, JCI insight.

[12]  Brian J. Bennett,et al.  Myeloid Slc2a1-Deficient Murine Model Revealed Macrophage Activation and Metabolic Phenotype Are Fueled by GLUT1 , 2019, The Journal of Immunology.

[13]  X. Fang,et al.  Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876 , 2018, Cancers.

[14]  A. Annoni,et al.  Detection and Characterization of CD8+ Autoreactive Memory Stem T Cells in Patients With Type 1 Diabetes , 2018, Diabetes.

[15]  H. Huthoff,et al.  Upregulation of Glucose Uptake and Hexokinase Activity of Primary Human CD4+ T Cells in Response to Infection with HIV-1 , 2018, Viruses.

[16]  P. Zhang,et al.  Enhanced glycolysis contributes to the pathogenesis of experimental autoimmune neuritis , 2018, Journal of Neuroinflammation.

[17]  P. Choudhary,et al.  Dynamic Profiling of Insulin Secretion and ATP Generation in Isolated Human and Mouse Islets Reveals Differential Glucose Sensitivity , 2017, Cellular Physiology and Biochemistry.

[18]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[19]  R. Curi,et al.  A past and present overview of macrophage metabolism and functional outcomes. , 2017, Clinical science.

[20]  J. Powell,et al.  Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation , 2017, The Journal of Immunology.

[21]  A. Carruthers,et al.  WZB117 (2-Fluoro-6-(m-hydroxybenzoyloxy) Phenyl m-Hydroxybenzoate) Inhibits GLUT1-mediated Sugar Transport by Binding Reversibly at the Exofacial Sugar Binding Site* , 2016, The Journal of Biological Chemistry.

[22]  F. Minutolo,et al.  Anticancer agents interacting with membrane glucose transporters. , 2016, MedChemComm.

[23]  T. Müller,et al.  Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876 , 2016, ChemMedChem.

[24]  E. Abraham,et al.  Pyruvate Dehydrogenase Kinase 1 Participates in Macrophage Polarization via Regulating Glucose Metabolism , 2015, The Journal of Immunology.

[25]  Susan R. Quinn,et al.  Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. , 2015, Cell metabolism.

[26]  J. Rathmell,et al.  The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. , 2014, Cell metabolism.

[27]  M. Troester,et al.  Metabolic Reprogramming of Macrophages , 2014, The Journal of Biological Chemistry.

[28]  B. Faubert,et al.  Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis , 2013, Cell.

[29]  Liang Zheng,et al.  Succinate is an inflammatory signal that induces IL-1β through HIF-1α , 2013, Nature.

[30]  J. Rathmell,et al.  Metabolic regulation of T lymphocytes. , 2013, Annual review of immunology.

[31]  J. Licht,et al.  Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. , 2013, Immunity.

[32]  Shiyong Wu,et al.  A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo , 2012, Molecular Cancer Therapeutics.

[33]  D. Green,et al.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. , 2011, Immunity.

[34]  M. Dwyer,et al.  Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation , 2011, Proceedings of the National Academy of Sciences.

[35]  P. Sutphin,et al.  Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality , 2011, Science Translational Medicine.

[36]  D. Green,et al.  HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells , 2011, The Journal of experimental medicine.

[37]  J. Rathmell,et al.  Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets , 2011, The Journal of Immunology.

[38]  W. Paul,et al.  Differentiation of effector CD4 T cell populations (*). , 2010, Annual review of immunology.

[39]  J. Rathmell,et al.  Glucose Uptake Is Limiting in T Cell Activation and Requires CD28-Mediated Akt-Dependent and Independent Pathways1 , 2008, The Journal of Immunology.

[40]  C. Thompson,et al.  The CD28 signaling pathway regulates glucose metabolism. , 2002, Immunity.

[41]  H. Shinomiya,et al.  Endotoxin-Induced Enhancement of Glucose Influx into Murine Peritoneal Macrophages via GLUT1 , 1995 .

[42]  H. Liu,et al.  Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. , 1994, Journal of immunology.

[43]  A. Carruthers,et al.  Equilibrium ligand binding to the human erythrocyte sugar transporter. Evidence for two sugar-binding sites per carrier. , 1987, The Journal of biological chemistry.